Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578349 | 1.00 | KDM1A (0.41) | KDM1AKDM1BBCHECES1HDAC1 | |
| SCHEMBL15047754 | 0.89 | KDM1A (0.36) | KDM1AKDM1BBCHECES1HDAC1 | |
| SCHEMBL29478809 | 0.86 | KDM1A (0.38) | KDM1AKDM1BBCHECES1HDAC1 | |
| SCHEMBL1224640 | 0.86 | KDM1A (0.38) | KDM1AKDM1BBCHECES1HDAC1 | |
| SCHEMBL10456466 | 0.83 | KDM1A (0.45) | KDM1AKDM1BBCHECES1ALDH1A1 | |
| SCHEMBL29620413 | 0.83 | KDM1A (0.45) | KDM1AKDM1BBCHECES1ALDH1A1 | |
| SCHEMBL375373 | 0.83 | KDM1A (0.50) | KDM1AKDM1BHDAC1HDAC6GPR3 | |
| SCHEMBL1478306 | 0.83 | KDM1A (0.45) | KDM1AKDM1BHDAC1HDAC6GPR3 | |
| SCHEMBL850836 | 0.83 | KDM1A (0.50) | KDM1AKDM1BBCHECES1ALDH1A1 | |
| SCHEMBL30228644 | 0.83 | KDM1A (0.45) | KDM1AKDM1BHDAC1HDAC6GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751104-A | Industrial preparation method of 2, 5-dimethyl-4-bromofluorobenzene | 清源创新实验室 | 2023-09-15 | — | — | CN | claimed |
| EP-3856734-B1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| CN-116751104-A | Industrial preparation method of 2, 5-dimethyl-4-bromofluorobenzene | 清源创新实验室 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751104-A | Industrial preparation method of 2, 5-dimethyl-4-bromofluorobenzene | 清源创新实验室 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751104-A | Industrial preparation method of 2, 5-dimethyl-4-bromofluorobenzene | 清源创新实验室 | 2023-09-15 | — | — | CN | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-03-21 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1029019-B1 | SUBSTITUTED POLY(ARYLENE VINYLENES), METHOD FOR PRODUCING THE SAME, AND THEIR USE IN ELECTROLUMINESCENT ELEMENTS | COVION ORGANIC SEMICONDUCTORS (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6638646-B2 | Polymerizing one or more monomers containing dihalogen containing substituted biaryls, via a base-induced dehydrohalogenation | SEMICONDUCTORS GMBH (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030088050-A1 | Substituted poly(arylenevinylenes), process for their preparation, and their use in electroluminescent elements | MERCK PATENT GMBH (DE) | 2003-05-08 | — | — | US | disclosed |
| US-20020064680-A1 | Substituted poly(arylene vinylenes), method for producing the same, and their use in electroluminescent elements | AXIVA GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| EP-1029019-A1 | SUBSTITUTED POLY(ARYLENE VINYLENES), METHOD FOR PRODUCING THE SAME, AND THEIR USE IN ELECTROLUMINESCENT ELEMENTS | Axiva GmbH (DE) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024526-A1 | SUBSTITUTED POLY(ARYLENE VINYLENES), METHOD FOR PRODUCING THE SAME, AND THEIR USE IN ELECTROLUMINESCENT ELEMENTS | AXIVA GMBH (DE) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | KDM1A 3905/4885KDM1B 4358/4885BCHE 1875/4885 |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | KDM1A 1032/4885KDM1B 886/4885BCHE 273/4885 |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | KDM1A 974/4885KDM1B 858/4885BCHE 261/4885 |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | KDM1A 974/4885KDM1B 858/4885BCHE 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.